Hosted on MSN9mon
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer
On Friday, Pfizer Inc (NYSE:PFE) released longer-term follow-up results from the Phase 3 CROWN trial evaluating Lorbrena (lorlatinib) available in Europe as Lorviqua versus Xalkori (crizotinib ...
pharmaphorum4d
After surging on lung cancer data, Ignyta looks to raise $160m
Pfizer’s Xalkori is already approved to treat patients with ROS1 mutations (alongside its use in ALK+ patients), but Ignyta’s drug looks likely to be superior, thanks in part to its ability to ...
pharmaphorum4d
Takeda sets sights on first-line lung cancer market with new Alunbrig data
Pfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a phase 3 trial. Takeda has reported updated results from its ALTA-1L trial ...
CURE12d
FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...